Dupixent

News

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT

News

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

Approval in COPD could unlock a $3 billion market opportunity for the drug, say analysts.

News

Dupixent works in hard-to-treat form of atopic dermatitis

IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.

News

Dupixent nears EU approval for rare skin disease prurigo nod...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease.

News

Weak data for Fasenra undermine AZ's ambitions for the drug

AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

Dupixent works in hard-to-treat form of atopic dermatitis

Dupixent nears EU approval for rare skin disease prurigo nod...

Weak data for Fasenra undermine AZ's ambitions for the drug

FDA clears Dupixent as first drug for rare skin disorder

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

Dupixent

Editor's Picks